Sumatriptan: Update and review

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 11, 2006, Pages 1503-1514

  Cady, Roger ^a   Schreiber, Curtis ^a  

^a HEADACHE CARE CENTER   (United States)

Author keywords

Migraine; Sumatriptan; Triptans

Indexed keywords

ALCOHOL; DIHYDROERGOTAMINE; FLUNARIZINE; NAPROXEN PLUS SUMATRIPTAN; PIZOTIFEN; PLACEBO; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

ANALGESIA; ARTICLE; BREAST FEEDING; BURNING SENSATION; CHILD CARE; CLINICAL TRIAL; CLUSTER HEADACHE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; FOOD AND DRUG ADMINISTRATION; FREQUENCY ANALYSIS; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; JOB PERFORMANCE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PARESTHESIA; PREGNANCY; PRESCRIPTION; PRESSURE SENSATION; PRODUCTIVITY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SINUS HEADACHE; SKIN TINGLING; TASTE DISORDER; THORAX PAIN; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG TOLERANCE; HUMANS; NAPROXEN; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 33746803676     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.11.1503     Document Type: Article

References (74)

1. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from th American Migraine Study II. Headache (2001) 41(7)646-657.
2. SCHER AI, STEWART WF, LIPTON RB: Epidemiology of chronic daily headache. In: Chronic Daily Headache for Clinicians. Goadsby PJ, Silberstein SD, Dodick DW (Eds). BC Decker, Inc., Hamilton, Ontario (2005):3-11.
3. STANG P, CADY R, BATENHORST A, HOFFMAN L: Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics (2001)18(3):231-244.
4. LIVEING E: Megrim, Sick Headache, and Some Allied Disorders: A Contribution to the Pathology of Nerve-Storms. Churchill (1873
5. SACKS O: Migraine: Understanding a Common Disorder. University of California Press, Berkley (1985):1-8, 228.
6. WOLFF HG: Headache and Other Head Pain, 2nd Edn. Oxford University Press, New York, NY (1963).
7. GARNER HH, SHULMAN B, MACNEAL PS, DIAMOND S: Psychiatric aspects of headache. Headache (1967) 7(1):1-12.
8. LANCE JW, ANTHONY M, GONSKI A: Serotonin, the carotid body, and cranial vessels in migraine. Arch. Neurol. (1967) 16(5):553-558.
9. SICUTERI F, ANSELMI B, FANCIULLACCI M: The serotonin (5-HT) theory of migraine. Neurology (1974) 4:383-394.
10. HUMPHREY PPA, FENIUK W, PERREN MJ, CONNOR HE, OXFORD AW, COATS IH: GR43175, a selective agonist for the 5-HT-1-like receptor in dog saphenous vein. Br. J. Pharmacol. (1988) 94:1123-1132.
11. MOSKOWITZ MA, BUZZI MG: Evidence for 5-HT1B/1D receptor mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia (1991) 11:165-168.
12. MOSKOWITZ MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology (1993) 43(Suppl. 3):S16-S20.
13. OLESEN J, DIENER HC, HUSSTEDT IW, GOADSBY PJ, HALL D, MEIER U: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. (2004) 350(11):1104-1110.
14. KAUBE H, HOSKIN K, GOADSBY PJ: Inhibition by sumatriptan of central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol. (1993) 109:788-792.
15. BURSTEIN R, JAKUBOWSKI M, LEVY D: Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain (2005) 115(1-2):21-28.
16. CADY RK, ADELMAN J, TAYLOR F, BOUDREAU G, FEW C, WEBSTER C: Speed of onset and efficacy of sumatriptan fast-disintegrating/rapid -release tablets: results of a randomised, placebo-controlled study conducted in the USA and Canada. Headache Care (2004) 1(4):281-284.
17. WALLS C, LEWIS A, BULLMAN J. et al.: Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin. (2004) 20(6):803-809.
18. FOWLER PA, LACEY LF, THOMAS M, KEENE ON, TANNER RJN, BABER NS: The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. (1991) 31:291-294.
19. PEROUTKA SJ: Sumatriptan in acute migraine: pharmacology and review of world experience. Headache (1990) 30(Suppl. 2):554-560.
20. MACINTYRE PD, BHARGAVA B, HOGG KJ, GEMMILL JD, HILLIS WS: Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 87(2):401-405.
21. SCOTT AK, WALLEY T BRECKENRIDGE AM, LACEY LF, FOWLER PA: Lack of interaction between propanolol and sumatripran. Br. J. Pharmacol. (1991) 32:581-584
22. VAN HECKEN AM, DEPRE M, DE SCHEPPER PJ, FOWLER PA, LACEY LF, DURHAM JM: Lack of effect of flunarinizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br. J. Pharmacol. (1992) 34:82-84.
23. SCOTT AK: Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. (1994) 27(5):337-344.
24. BLIER P, BERGERON R: The safety of concomitant use of sumatriptan and antidepressant treatments. J. Clin. Psychopharmacol. (1995) 15:106-109.
25. LEUNG M: Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache (1995) 35:488-489.
26. CADY RK, WENDT JK, KIRCHNER JR, SARGENT JD, ROTHROCK JF, SKAGGS H: Treatment of acute migraine with subcutaneous sumatriptan. JAMA (1991) 265:2831-2835.
27. THE SUBCUTANEOUS SUMATRIPTAN INTERNATIONAL STUDY GROUP: Subcutaneous sumatriptan in the acute treatment of migraine. N. Engl. J. Med. (1991) 325:316-321.
28. HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic citeria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia (1988) 8(Suppl.):18-28.
29. CADY RC, RYAN R, JHINGRAN P, O'QUINN S, PAIT DC: Sumatriptan injection reduces productivity loss during a migraine attack, results of a double-blind, placebo-controlled trial. Arch. Int. Med. (1998) 158(9):1013-1018.
30. SCHULMAN EA, CADY RK, HENRY D: Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin. Proc. (2000) 75:782-789.
31. WENDT J, CADY R, SINGER R et al.: A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin. Ther. (2006) 28(4):517-526.
32. DIAMOND S, ELKIND A, JACKSON T, RYAN R, DEBUSSEY S, ASGHARNEJAD M: Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch. Fam Med. (1998) 7:234-240.
33. PFAFFEHRATH V, CUNIN G, SJONELL G, PENDERGAST S: Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimal doses of oral sumatriptan. Headache (1998) 38:184-190.
34. SARGENT J, KIRCHNER JR, DAVIS R, KIRKHART B: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. (1995) 45(Suppl. 7):S10-S14.
35. CUTLER N, MUSHET GR, DAVIS R, CLEMENTS B, WHITCHER L: Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology (1995) 45(Suppl. 7):S5-S9.
36. DAHLÖF C, CADY R, POOLE AC, BRANDES J, FEW C, JONES M: Speed of onset and efficacy of sumatriptan fast-disintegrating rapid-release tablets: pooled results of two replicate, randomized, placebo-controlled studies. Headache Care (2004) 1(4):277-280.
37. BRANDES JL, O'CARROLL PC, MANNIX LK, LENER SE, LITTLEFIELD D, ALEXANDER WJ: Therapeutic clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT technology and naproxen sodium. Presented at the 12th Congress of the International Headache Society. Kyoto, Japan (2005).
38. WINNER PK, CADY RK, RUOFF G, FRISHBERG BM, ZHANG Y, ALEXANDER JW: Long term safety and tolerability of a fixed single-tablet formulation of sumatriptan RT Technology™ and naproxen sodium in the acute treatment of migraine. Accepted for platform presentation American Headache Society.
39. SILBERSTEIN SD, STARK S, DEROSSETT SE, TAYLOR D, MCDONALD SA, LENER S: Superior clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT Technology™ and naproxen sodium. Presented at the American Academy of Neurology 58th Annual Meeting. San Diego, CA (2006) S35:001.
40. CADY RK, LIPTON RB, HALL C, STEWART WF, O'QUINN S, GUTTERMAN D: Treatment of mild headache in disabled headache sufferers: results of the spectrum study. Headache (2000) 40:792-797.
41. WINNER P, MANNIX LK, PUTNAM G, MCNEAL S, KWONG J, O'QUINN S: Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double blind, placebo controlled studies. Mayo Clin. Proc. (2003) 78:1214-1222.
42. PASCUAL J, CABARROCAS X: Within-patient early versus delayed treatment of migraine attacks with the sooner the better. Headache (2002) 42(1):28-31.
43. BRANDES JL, KUDROW D, CADY R, TISEO PJ, SUN W, SIKES CR: Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia (2005) 25(9):735-742.
44. CADY RK, ELKIND A, GOLDSTEIN J, KEYWOOD C: Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr. Med. Res. Opin. (2004) 20(9):1465-1472.
45. CADY R, MARTIN V, MAUSKOP A, RODGERS A, HUSTAD CM, RAMSEY KE: Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache (submitted).
46. FERRARI MD: Should we advise patients to treat migraine attacks early: methodologic issues. Eur. Neurol. (2005) 53(Suppl. 1):17-21.
47. TFELT-HANSEN P, BLOCK G, DAHLOF C, DIENER H-C, FERRARI MD, GOADSBY PJ: Guidelines for controlled trials of drugs in migraine:second edition. Cephalalgia (2000) 20:765-786.
48. BURSTEIN R, YARNITSKY D, GOOR-ARYEH I, RANSIL BJ, BAJWA ZH: An association between migraine and cutaneous allodynia. Ann. Neurol. (2000) 47:614-624.
49. LEVY D, JAKUBOWSKI M, BURSTEIN R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl Acad. Sci. USA (2004) 101:4274-4279.
50. BURSTEIN R, COLLINS B, JAKUBOWSKI M: Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol (2004) 55:18-26.
51. LIPTON RB, STEWART WF, CADY RK et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study. Recipient of 2000 Wolff Award. Headache (2000) 40:783-791
52. LIPTON RB, CADY RK, STEWART WF, WILKS K, HALL C: Diagnostic lessons from the spectrum study. Neurology (2002) 58(9 Suppl. 6):S27-S31.
53. TEPPER SJ, CADY RK, DODICK D et al.: Oral sumatriptan for treatment of probable migraine: first randomized controlled study. Headache (2006) 46:1-10.
54. The International Classification of Headache Disorders 2nd Edition. Cephalalgia (2004) 24(Suppl. 1):1-160.
55. CADY RK, SCHREIBER CP: Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology (2002) 58(Suppl. 6):S10-S14.
56. SCHREIBER CP, HUTCHINSON S, WEBSTER CJ, AMES M, RICHARDSON MS, POWERS C: Prevalence of migraine in patients with a history of self-reported or physician-diagnosed 'sinus' headache. Arch. Intern Med (2004) 164(16):1769-1772.
57. ISHKANIAN C, BLUMENTHAL H, POWERS C, WEBSTER C, RICHARDSON MS: Sumatriptan is effective in migraine presenting as sinus headache. Poster presentation at Headache Update 2002. Orlando, FL (2002).
58. EKBOM K, MONSTAD I, PRUSINSKI A, COLE JA, NORONHA D: Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol. Scand. (1993) 88:63-69.
59. HERSHEY AD, POWERS SW, LECATES S, BENITTI AL: Effectiveness of nasal sumatriptan in 5 - 12 year old children. Headache (2001) 41:693-697.
60. UEBERALL MA, WENZEL D: Intranasal sumatriptan for acute treatment of migrain in children. Neurology (1999) 52:1507-1513.
61. WINNER P, ROTHNER D, SAPER J et al.: A randomized, double-blind, placebo-controlled, study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics (2000) 106:989-997.
62. WINNER P, ROTHNER D, WEBSTER C et al.: Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology (2004) 62(Suppl. 5): 182.
63. CURRAN MP, EVANS HC, WAGSTAFF AJ: Intrnasal sumatriptan in adolescents with migraine. CNS Drugs (2005) 18(4):335-343.
64. HOUGHTON LA, FOSTER JM, WHORWELL PJ, MORRIS J, FOWLER P: Is chest pain after sumatriptan oesophageal in origin? Lancet (1994) 344:985-986.
65. BOSKA MD, WELCH KMA, SCHULTZ L, NELSON J: Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia (2000) 20:39-44.
66. TANSEY MJB, PILGRIM AJ, MATIN PM: Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol. (1993) 33:310-315.
67. WELCH KM, MATHEW NT, STONE P, ROSAMOND W, SAIERS J, GUTTERMAN D: Tolerability of sumatriptan: clinical trials and post marketing experience. Cephalalgia (2000) 20:687-695.
68. DODICK D, LIPTON RB, MARTIN V et al.: Triptan Cardiovascular Safety Expert Panel: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache (2004) 44(5):414-425.
69. THE SUMATRIPTAN AND NARATRIPTAN PREGNANCY REGISTRY: Interim report, 1 January 1996 - 3O April 2006: data available from GlaxoSmithKline.
70. HALE TW: Medications and Mother's Milk, 11th edn. Pharmasoft Publishing, Amarillo, TX (2004).
71. JHINGRAN P, CADY RK, RUBINO J, MILLER D, GRICE RB, GUTTERMAN DL: Improvement in health-related quality of life with sumatriptan treatment for migraine. J. Fam. Pract. (1996) 42:36-42.
72. CADY RK, RYAN R, JHINGRAN P, O'QUINN S, PATT G: Sumatriptan injection reduces productivity loss during a migraine attack. Arch. Intern. Med. (1998) 158:1013-1018
73. ADELMAN JU, SHARFMAN M, JOHNSON R, MILLER D, CLEMENTS B, PATT G: Impact of oral sumatriptan on workplace productivity, health related quality of life, healthcare use and patient satisfaction with medication in nurses with migraine. Am. J. Man. Care. (1996) 2:1407-1416.
74. HALPERN MT, LIPTON RB, CADY RK, KWONG WJ, MARLO KO, BATENHORST AJ: Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache (2002) 42(10):984-999.